Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS · Delayed Price · Currency is USD
0.2585
+0.0086 (3.44%)
Oct 27, 2025, 3:59 PM EDT
Northwest Biotherapeutics Revenue
Northwest Biotherapeutics had revenue of $131.00K in the quarter ending June 30, 2025, a decrease of -74.31%. This brings the company's revenue in the last twelve months to $1.09M, down -33.50% year-over-year. In the year 2024, Northwest Biotherapeutics had annual revenue of $1.38M, down -28.47%.
Revenue (ttm)
1.09M
Revenue Growth
-33.50%
P/S Ratio
360.67
Revenue / Employee
43.76K
Employees
25
Market Cap
394.58M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.38M | -550.00K | -28.47% |
| Dec 31, 2023 | 1.93M | 249.00K | 14.80% |
| Dec 31, 2022 | 1.68M | 678.00K | 67.46% |
| Dec 31, 2021 | 1.01M | -286.00K | -22.15% |
| Dec 31, 2020 | 1.29M | -1.12M | -46.43% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| China New Energy Group Co. | 12.51M |
| Nuo Therapeutics | 1.95M |
Northwest Biotherapeutics News
- 3 days ago - Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed - PRNewsWire
- 2 months ago - Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd. - PRNewsWire
- 2 months ago - Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman - PRNewsWire
- 4 months ago - Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments - PRNewsWire
- 6 months ago - Northwest Biotherapeutics: A Spike On Their Expected Imminent Approval - Seeking Alpha
- 10 months ago - Northwest Biotherapeutics announces $5M convertible note financing and standby facility for up to $50M additional financing - Seeking Alpha
- 10 months ago - Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing - PRNewsWire
- 11 months ago - Northwest Biotherapeutics: All Is Not Well With This One - Seeking Alpha